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Abstract The sustained integrity of the mitochondrial
population of a cell is critical for maintained cell health,
and disruption of that integrity is linked strongly to
human disease, especially to the neurodegenerative dis-
eases. These are appalling diseases causing untold levels
of suffering for which treatment is woefully inadequate.
Understanding the mechanisms that disturb mitochondri-
al homeostasis may therefore prove key to identification
of potential new therapeutic pathways. Mechanisms
causing mitochondrial dysfunction include the acute cat-
astrophic loss of function caused by opening of the
mitochondrial permeability transition pore (mPTP),
which collapses bioenergetic function and initiates cell
death. This is best characterised in ischaemic reperfu-
sion injury, although it may also contribute to a number
of other diseases. More insidious disturbances of mito-
chondrial homeostasis may result from impaired balance
in the pathways that promote mitochondrial repair
(biogenesis) and pathways that remove dysfunctional
mitochondria (mitophagy). Impaired coordination be-
tween these processes is emerging as a key feature of
a number of neurodegenerative and neuromuscular dis-
orders. Here we review pathways that may prove to be
valuable potential therapeutic targets, focussing on the
molecular mechanisms that govern the coordination of
these processes and their involvement in neurodegener-
ative diseases.
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Introduction
Mitochondria lie at the heart of energy provision for most cells
and tissues, providing energy for the balance against negative
entropy, for maintenance of cell structure and for active sig-
nalling. As mitochondria are crucial for the maintenance of
cellular homeostasis, including ATP production and intracel-
lular calcium regulation, and mitochondria regulate routes to
cell death (reviewed in Osellame et al. 2012), it is hardly
surprising that processes that disturb mitochondrial integrity
lead to disease or to death.
Structurally, mitochondria are compartmentalised by two pro-
tein containing lipid bilayers: the external outer mitochondrial
membrane (OMM), the inter membrane space (IMS) and the
matrix, which is enclosed by the inner mitochondrial membrane
(IMM) that is intensely but variably folded into cristae, which
vastly expand the membrane surface area available for the bio-
energetic transformations that are fundamental to mitochondrial
function. The inner mitochondrial membrane houses the protein
complexes of the electron transport chain, and provides a highly
efficient and selective barrier to the flow of ions. The mitochon-
drial matrix contains the enzymes that drive the tricarboxylic acid
cycle and beta-oxidation. The outermitochondrialmembrane has
a less tightly regulated permeability, which allows the passage of
low molecular weight substances, between the cytosol and the
mitochondrial intermembrane space. The cross talk and transport
of metabolites and proteins between the mitochondria and the
rest of the cell are critical in mitochondrial biogenesis, in main-
taining the competence of oxidative phosphorylation and pro-
duction of ATP (reviewed in Kotiadis et al. 2014).
Mitochondrial biogenesis
Mitochondrial biogenesis is the process by which cells gener-
ate new mitochondrial protein and, if required, increase
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mitochondrial mass. This is of necessity a complex and so-
phisticated process, as it requires the coordinated transcription
and translation of two genomes, and so includes the import of
nuclear encoded proteins, and the assembly of both mitochon-
drial and nuclear-derived products into an expanding mito-
chondrial reticulum, coupled to the recruitment of newly
synthesized lipids (Dominy and Puigserver 2013; Zhu et al.
2013). At the molecular level, several transcription factors and
cofactors are involved in the activation and regulation of
mitochondrial biogenesis, in response to diverse stimuli, such
as nutrient availability, hormones, growth factors and temper-
ature fluctuations. These factors include: the ubiquitous tran-
scription factors (SP1, YY1, CREB, MEF2/E-box), nuclear
respiratory factors 1 and 2 (NRF1-2), REBOX/OXBOX,MT1
to 4 and estrogen-related receptors (ERRα, ERRβ, ERRγ)
that work in concert with transcriptional coactivators of the
peroxisome proliferator-activated receptor gamma coactivator
1α (PGC1α) family, (PGC1α, PGC1β and PGC1-related
coactivator) (Dominy and Puigserver 2013; Puigserver et al.
1999; Scarpulla 2002).
PGC1α acts as a master regulator of mitochondrial biogen-
esis and energy metabolism and has the capability to integrate
and coordinate the activity of multiple transcription factors,
such as NRF1-2, PPARα and mitochondrial transcription
factor A (mtTFA) (Dominy and Puigserver 2013; Puigserver
et al. 1998). NRF1 and NFR2 govern the expression of
multiple nuclear encoded mitochondrial proteins. For exam-
ple, they regulate the transcription of mtTFA and transcription
factor B proteins, which are in turn regulators of mitochondri-
al DNA transcription and replication (Dominy and Puigserver
2013; Gleyzer et al. 2005; Scarpulla 2008). Moreover, the
transcriptional activity of NRF1 is linked to the expression
of nuclear genes encoding subunits of the mitochondrial re-
spiratory complexes, proteins related to mitochondrial import
machinery, enzymes of haem biosynthesis, tRNA synthases
and mitochondrial ribosomal proteins (Scarpulla 2008).
Estrogen-related receptors (ERRα, ERRβ, ERRγ) are mem-
bers of the nuclear hormone receptor family, and promote
mitochondrial biogenesis in response to hormonal signals.
ERRα regulates the transcription of nuclear genes encoding
mitochondrial related factors, including proteins of the Krebs
cycle, of mitochondrial fission and fusion, oxidative phos-
phorylation and of fatty acid oxidation (Dominy and
Puigserver 2013).
Peroxisome proliferator-activated receptors (PPAR) are li-
gand activated transcription factors that belong to the nuclear
hormone receptor superfamily, and are intimately involved in
the regulation of mitochondrial biogenesis. The PPAR recep-
tors include PPARα, PPARγ and PPARβ/δ. These pathways
are subject to pharmacological control—PPARγ is activated
by the thiazolidinediones, a group of drugs that regulate
glucose metabolism, adipogenesis, differentiation, and the
expression of several genes including antioxidant defences
and inflammatory cytokines (Chung et al. 2008; Dello Russo
et al. 2003; Jung et al. 2007; Nolan et al. 1994; Tontonoz et al.
1994). PPARγ agonists increase mitochondrial biogenesis,
increasing the expression of PGC1α, NRF1-2, and mtTFA
with a consequent increased mitochondrial DNA (mtDNA)
copy number, increased oxygen consumption and an in-
creased capacity for oxidative phosphorylation (Bogacka
et al. 2005; Corona et al. 2014; Ghosh et al. 2007; Miglio
et al. 2009; Strum et al. 2007).
Mitochondrial biogenesis as target for neuroprotection
A number of studies have suggested potential roles for factors
that regulate mitochondrial biogenesis in several neurodegen-
erative disorders. Thus, in mouse models of mitochondrial
diseases the overexpression of PGC1α showed robust induc-
tion of mitochondrial biogenesis and increased the mitochon-
drial respiratory chain activity (Viscomi et al. 2011). Addi-
tionally, studies in human cells with complex III or IV defi-
ciencies showed that increased expression of PGC1α, and/or
its homologue PGC1β, improved mitochondrial respiration
(Srivastava et al. 2009).
In cellular models of Parkinson’s disease (PD), the activa-
tion of PGC1α increased the expression of nuclear-encoded
subunits of the mitochondrial respiratory chain and prevented
the dopaminergic neuron loss induced by mutant α-synuclein
or by the pesticide rotenone (Zheng et al. 2010). Recently it
was shown that adenoviral delivery of PGC1α in the
nigrostriatal system increased dopaminergic death (Ciron
et al. 2012). This effect was explained by the excessive
overexpression of PGC1α, resulting in mitochondrial hyper-
activity and increased production of ROS. The overexpression
of PGC1α in the SN was shown to reduce the expression of
tyrosine hydroxylase (TH). The reduced TH expression was
associated with loss of Pitx3, a transcription factor that is
critical for the development and maintenance of dopaminergic
cells. Expression of the neurotrophic factor BDNF, which is
also regulated by Pitx3 was reduced. Therefore, the overex-
pression of PGC1α resulted in dopamine depletion associated
with lower levels of Pitx3 and enhanced susceptibility to
MPTP (Clark et al. 2012). Thus, studies of the role of PGC1α
in relation to PD have provided inconsistent data.
While PGC1α is regulated at the transcriptional level,
several post-translational modifications (phosphorylation,
acetylation, SUMOylation, and methylation) (Puigserver and
Spiegelman 2003; Rytinki and Palvimo 2009) and interactions
may also be relevant for the maintenance of the metabolic
competence of neurons. In that sense, and linking PGC1α
biology to PD, it has been shown that the inactivation of DJ-1
(in which mutations associate with familial PD) causes de-
creased expression of human MnSOD. It seems that DJ-1
stimulates the activity of PGC1α, in turn influencing the
90 J Bioenerg Biomembr (2015) 47:89–99
transcription of MnSOD. Although DJ-1 does not interact
with PGC1α directly, it inhibits the SUMOylation of a tran-
scriptional repressor, pyrimidine tract-binding protein-associ-
ated splicing factor (PSF). PSF binds PGC1α and suppresses
its transcriptional activity. SUMO-specific isopeptidase
SENP-1 further enhances the synergy between DJ-1 and
PGC1α, whereas a SUMO E3 ligase protein inhibitor of
activated STAT Y completely blocks the synergy. Conversely,
oxidative modification renders DJ-1 unable to inhibit
SUMOylation, attenuating the transcriptional synergy be-
tween DJ-1 and PGC1α, and linking oxidative stress, DJ-1
dysfunction and PGC1α function, all associating with the
pathophysiology of PD. Finally, the transcriptional dysregu-
lation caused by the inactivation of DJ-1, either by pathogenic
mutations or oxidation, could result in defective mitochondrial
gene regulation that may contribute to the development of
sporadic PD (Zhong and Xu 2008).
In a conditional knockout mouse with disruption of the
gene for mtTFA, mtDNA expression and respiratory chain
deficiency were reduced in dopaminergic neurons (Ekstrand
et al. 2007). However, the overexpression of mtTFA and
NRF1 in neuronal cells protected against MPP+-induced mi-
tochondrial dysfunction in SHSY-5Y cells in culture (Piao
et al. 2012). The PPARγ agonist rosiglitazone increased mi-
tochondrial biogenesis, and increased oxygen consumption in
sporadic and PINK1-associated PD cellular models (Corona
et al. 2014).
Intriguingly, mitochondrial dysfunction, defective bio-
energetics, striatal degeneration and a hyperkinetic move-
ment disorder, features of Huntington’s disease (HD),
were described in PGC1α knockout mice (Leone et al.
2005; Lin et al. 2004). The PGC1α knockout mice
showed impaired motor performance, degeneration and
an increased susceptibility to the mitochondrial complex
II inhibitor, 3-nitropropionic acid, which alone causes a
HD like illness in mice and is often used to model the
disease. In similar vein, expression of PGC1α delivered
into the striatum of HD transgenic mice using a lentiviral
vector was neuroprotective (Cui et al. 2006). Indeed,
overexpression of PGC1α enhanced the mitochondrial
membrane potential and reduced mitochondrial toxicity
in models of HD (Weydt et al. 2006). The PPARγ agonist
rosiglitazone similarly increased mitochondrial biogenesis
in striatal cells and protected against thapsigargin-induced
mitochondrial dysfunction in mutant huntingtin-
expressing cells (Quintanilla et al. 2008). In a transgenic
mouse model of HD, treatment with rosiglitazone reduced
huntingtin aggregates and normalized the expression of
PGC1α, NRF1, NRF2 and mtTFA in the cortex. Also,
rosiglitazone restored the reduced mitochondrial mass in
mutant huntingtin expressing N2a cells (Chiang et al.
2012). The pan-PPAR agonist bezafibrate increased the
numbers of muscle mitochondria, increased mitochondrial
biogenesis and improved the phenotype, improved surviv-
al and reduced brain, muscle and BAT pathology in HD
mice (Johri et al. 2012).
In the SOD1-G93A mouse model of familial amyotrophic
lateral sclerosis (ALS), the elevation of PGC1α levels
sustained mitochondrial biogenesis through end-stage disease
and this activity was accompanied by retention of muscle
function, delayed muscle atrophy, and significantly improved
muscle endurance even at late stages of disease. However,
survival was not extended (Da Cruz et al. 2012). In double
transgenic mice overexpressing G93A mutant SOD1 and
human mtTFA, the overexpression of mtTFA reduced indices
of oxidative stress in motoneurons and delayed the onset of
the disease in SOD1-G93A mice (Morimoto et al. 2012).
Similarly, expression of PGC1α protected against mitochon-
drial fragmentation and reduced neuronal cell death in cul-
tured motoneurons from SOD1-G93A rat and mouse models
(Song et al. 2013).
In Alzheimer’s disease (AD) postmortem brain, PGC1α
messenger RNA expression was significantly decreased, cor-
relating with the progression of clinical dementia in the AD
brain. Interestingly, PGC1α expression in primary cultures of
cortico-hippocampal neurons derived from Tg2576 AD mice
reversed glucose-induced amyloid-beta (Aβ) peptide produc-
tion (Qin et al. 2009). PGC1α overexpression in N2a neuro-
blastoma cells also decreased secreted Aβ and increased the
levels of non-amyloidogenic soluble Aβ (Katsouri et al.
2011). Furthermore, a genetic variant in mtTFA has been
identified as a moderate risk factor for AD, suggesting that
disturbed maintenance of mtDNA integrity or mitochondrial
function may underlie neurodegeneration (Belin et al. 2007).
Overexpression of mtTFA protected SH-SY5Y cells from
Aβ-induced mitochondrial dysfunction (Xu et al. 2009). In
both hippocampal tissues from mouse AD models and M17
cells expressing mutant amyloid precursor protein (APPswe),
expression levels of PGC1α, NRF1, NRF2, and mtTFAwere
significantly decreased, suggesting reduced mitochondrial
biogenesis. Nevertheless, overexpression of PGC1α exacer-
bated the impaired mitochondrial biogenesis and mitochon-
drial deficits in APPswe M17 cells (Sheng et al. 2012). The
transcription factors implicated in the regulation of mitochon-
drial biogenesis are summarised in (Fig. 1).
Autophagy
Autophagy is an evolutionarily conserved catabolic process
that mediates the degradation of long-lived proteins and dys-
functional or superfluous organelles. Autophagy is induced by
various adverse conditions such as limited nutrients, low
oxygen levels, and decreased energy supply, and its action
results in the release of degradation products, especially amino
acids, back into the cytoplasm to be used in essential
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biosynthetic pathways (He and Klionsky 2009; Kundu and
Thompson 2008; Levine and Kroemer 2008; Mizushima et al.
2008). The autophagic degradation routes are classified into
three different pathways: macroautophagy, microautophagy,
and chaperone-mediated autophagy (Massey et al. 2006;
Mizushima 2009; Tolkovsky 2009). Macroautophagy is the
major lysosomal pathway for the turnover of cytoplasmic
components. During macroautophagy, portions of the cyto-
plasm are engulfed by a double-membrane phagophore that
expands into a cytosolic vesicle called autophagosome; the
completed autophagosome is targeted to the lysosome. The
outer membrane of the autophagosome subsequently fuses
with the lysosomal membrane, allowing hydrolases access to
the inner autophagosome membrane and its cargo, which is
degraded and recycled. Macroautophagy can mediate nonse-
lective and bulk degradation of cytoplasmic contents, includ-
ing entire organelles (Kundu and Thompson 2008). Finally,
the autophagic load is degraded and the resulting essential
biomolecules are recycled back to the cytoplasm to satisfy the
anabolic and energetic requirements of the cell (Mizushima
2009). Among the three main types of autophagy,
macroautophagy is the best characterized process and will
hereafter be referred to as autophagy.
Autophagy as a target for neuroprotection
In the CNS the accumulation of defective organelles and/or
protein aggregates resulting from autophagic failure, may
disturb axonal traffic and enhance neuronal toxicity (Nixon
et al. 2008). Moreover, the autophagic machinery is required
for the remodelling of neuronal dendrites and axons and hence
for maintaining CNS plasticity (Fimia et al. 2007; Komatsu
et al. 2007; Pickford et al. 2008;Wang et al. 2006). In neurons,
the autophagic pathway and the ubiquitin proteasome system
(UPS) are the major cellular routes for protein turnover. UPS-
mediated degradation requires substrate proteins to unfold and
pass through the narrow pore of the proteasomal barrel. As a
result, autophagy is the main route for the degradation of toxic
aggregate proteins, either in their oligomeric or in their
aggregate forms. Therefore, dysregulation of autophagy has
been proposed as a pathogenic mechanism contributing to
several neurodegenerative disorders (Wong and Cuervo
2010).
In particular, there has been great excitement in recent
years over possible roles of impaired autophagy in the patho-
physiology of PD. In PD there is a long literature pointing
towards defects in mitochondrial function, especially in rela-
tion to impaired complex I function (Schapira et al. 1990).
This connection has been strengthened by the actions of toxins
that target complex I (MPTP, rotenone) which cause a PD like
neurodegeneration in animal models (Alam and Schmidt
2002; Betarbet et al. 2000; Corona et al. 2010). Further, whilst
the occurrence of PD in man is predominantly sporadic and
age related, a number of patients have familial forms of the
disease. The systematic identification of mutations that in-
crease the risk of PD, including genome wide association
studies, has generated an ever-increasing list of proteins asso-
ciated with PD (Bonifati 2012). Remarkably, a number of
these lie on the pathways of autophagy. These include PINK1,
that signals on the outer membrane of dysfunctional mito-
chondria to recruit the ubiquitin ligase Parkin, another PD
related gene, and initiates removal of dysfunctional mitochon-
dria by autophagy. Other PD associated proteins linked to the
autophagy pathway include fbxo7 (Burchell et al. 2013),
LRRK2 (Manzoni et al. 2013) and intriguingly the protein
glucocerebrosidase (GBA), which lies on the lysosomal end
of the pathway. Mutations of GBA give rise to the lysosomal
storage disease, Gaucher disease, but mutations of GBA also
carry the highest known risk of developing PD (Mazzulli et al.
2011; Sidransky et al. 2009). In a recent study (Osellame et al.
2013), we showed that in neurons cultured from the CNS of
GBA knockout mice, autophagy was down regulated, mito-
chondrial function was profoundly compromised and there
was early accumulation of α-synuclein, the major component
of Lewy bodies, the pathological signature of PD which
reflects also a failure of UPS mediated protein degradation
pathways. Activities of respiratory complex I, II and III were
impaired, mitochondria were fragmented, mass was increased
but potential was decreased. Interestingly, the potential could
be recovered after incubating the cells with MitoQ, an antiox-
idant targeted to complex I supporting a model whereby
mitochondrial damage starts to accumulate as autophagic
removal fails, leading to increased ROS generation, ROS
mediated damage to the respiratory complexes, providing
the basis for a destructive cycle that will lead to the progres-
sive bioenergetic collapse culminating in cell death.
The pharmacological stimulation of autophagy has there-
fore been heralded as a novel and promising clinical strategy
for the treatment of some neurodegenerative disorders. The
mammalian target of rapamycin (mTOR), a master regulator
of nutrient and growth factor signalling, is one of the critical
components involved in controlling the induction of
Fig. 1 Mitochondrial biogenesis, autophagy and mPTP involved in
neuroprotection. There are transcription factors that are intimately
implicated in the regulation of mitochondrial biogenesis such as
PGC1α, NRF1-2, mtTFA and PPARγ, also there are compounds like
resveratrol that can stimulate mitochondrial biogenesis and protect
against several neurodegenerative disorders. When autophagosome
formation is impaired, mTOR-dependent and/or mTOR-independent
autophagy upregulation may counteract neurodegeneration through the
stimulation of autophagosome formation, also beclin1, starvation or
compounds like resveratrol may stimulate autophagy. The mitochondrial
channel mPTP is mainly associated with release of mitochondrial death
signals and induction of apoptosis, therefore, mPTP inhibitors like CsA,
antioxidants and the CypD deficiency, may be neuroprotective
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autophagy (He and Klionsky 2009). In most cell types, mTOR
activity is necessary and sufficient to suppress autophagy
under favourable growth conditions. In fact, it has been re-
ported that inhibition of mTOR with rapamycin induced au-
tophagy and reduced toxicity of polyglutamine expansions in
fly and mouse models of HD (Ravikumar et al. 2004). There
are other chemical agents capable of inducing autophagy in an
mTOR-independent manner. In that sense, lithium treatment
induced mTOR-independent autophagy by inhibiting inositol
monophosphatase and protected against neurodegeneration in
an HD fly model (Sarkar et al. 2008). The mTOR independent
autophagy inducer trehalose alleviated polyglutamine-
mediated pathology in a mouse model of HD (Tanaka et al.
2004). Other studies have shown that elevation of the lyso-
somal proteases accelerated clearance of mutant huntingtin
from HEK cells through an autophagic mechanism (Liang
et al. 2011).
Several in vitro studies have demonstrated that induction of
autophagy with different compounds such as resveratrol (Wu
et al. 2011), kaempferol (Filomeni et al. 2012) and
Isorhynchophylline (Lu et al. 2012), resulted in improvements
in different models of PD. Also, beclin 1 (a regulator of the
autophagy pathway) gene transfer activated autophagy and
ameliorated the neurodegenerative pathology in α-synuclein
models of PD/Lewy body diseases (Spencer et al. 2009). The
administration of a lentiviral vector expressing beclin 1 re-
duced both intracellular and extracellular Aβ pathology in
APP transgenic mice model of AD (Pickford et al. 2008).
Moreover, resveratrol reduced neurodegeneration in the hip-
pocampus and prevented learning impairment in a model of
AD (Kim et al. 2007). In SOD1-G93A mice, daily adminis-
tration of lithium delayed ALS progression and the neuropro-
tection was accompanied by the activation of autophagy in
motoneurons (Fornai et al. 2008). Upregulation of autophagic
genes displayed similar results in Caenorhabditis elegans
model of ALS (Li et al. 2013). The molecular chaperone
trehalose (Gomes et al. 2010) and resveratrol (Kim et al.
2007) have also shown protection against neurodegeneration
in models of ALS. Food restriction or starvation, another
established autophagy inducer, protected the spinal cord of
SOD1-G93Amice, only at onset stage but not at pre-end stage
of ALS (Zhang et al. 2013). However, rapamycin augmented
motoneuron degeneration in the SOD1-G93A mice (Zhang
et al. 2011). The factors implicated in the stimulation of
autophagy are summarised in (Fig. 1).
mPTP
Opening of the mitochondrial permeability transition pore
(mPTP) mediates a catastrophic increase in the permeability
of the inner mitochondrial membrane that collapses the po-
tential, preventing ATP synthesis and leading to cell death. Its
molecular identity is controversial. There has been a broad
consensus that the pore represents a conformational change of
components of the inner mitochondrial membrane that have
another function in normal respiring mitochondria. Currently,
the favoured candidate is the F1Fo-ATP synthase (Alavian
et al. 2014; Giorgio et al. 2013). Currently, the only certain
component of the pore complex is cyclophilin D, (CypD)
which acts as a regulator of pore opening. The involvement
of CypD is crucial, as it renders the pore accessible to phar-
macological intervention through cyclosporin A (CsA) and
related compounds.
The opening of the mPTP leads to a transition in perme-
ability of the inner membrane from extremely low to freely
permeable to solutes up to 1.5 kDa. The mPTP can be opened in
cells and respiring isolated mitochondria by Ca2+ overload
and by pro-oxidants, modulated by adenine nucleotides and
by phosphate (Gunter and Pfeiffer 1990; Halestrap 2009). The
open mPTP may be closed by removal of Ca2+ with EGTA or
the addition of ADP, Mg2+, or CsA (Bernardi and von
Stockum 2012; Crompton et al. 1988; Dube et al. 2012).
The opening of mPTP is classically initiated by an increase
in matrix Ca2+ in the presence of phosphate, while depletion
of adenine nucleotides, oxidative stress or a decrease in mito-
chondrial potential lower the threshold for Ca2+ dependent
opening of the pore or mitochondria are depolarized by FCCP
(Crompton and Costi 1990; Scorrano et al. 1997). Moreover,
higher Ca2+ concentrations are needed for pore opening in the
presence of inhibitors including high negative membrane
potential, low matrix pH, ADP, Sr and Mg2+ (Bernardi and
von Stockum 2012; Kinnally et al. 2011). The rapid removal
of Ca2+ from the cytosol through mitochondrial Ca2+ uptake
and its subsequent release from mitochondria through mPTP
flickering could prevent Ca2+-inactivation of plasma mem-
brane channels essential to refilling Ca2+ stores while allowing
signalling in these microdomains (Pastorino et al. 1999).
Mitochondrial Ca2+ overload leads to the induction of the
mPTP, resulting in osmotic swelling and a collapse of the
mitochondrial membrane potential. This will cause complete
bioenergetic collapse and will lead inevitably to necrotic cell
death in most cell types. In cells with a high glycolytic
capacity, the swelling, the resulting rupture of the outer mem-
brane and the release of pro-apoptotic factors into the cytosol
may initiate apoptotic cell death (Kinnally et al. 2011; Ryu
et al. 2010). The specific role of the mPTP in apoptotic cell
death has been somewhat controversial—thus knockout of
CypD was protective against necrotic but not apoptotic cell
death (Li et al. 2004; Nakagawa et al. 2005).
mPTP opening is different in liver and brain mitochondria,
as the liver mitochondria have lower Ca2+ capacity than brain
mitochondria (Panov et al. 2007). The brain mitochondria are
less sensitive to the damaging effect of Ca2+ and are less
sensitive to the protective effect of CsA during Ca2+ load.
The osmotic swelling of the brain mitochondria is rather small
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in comparison with liver mitochondria. Interestingly, liver and
neuronal cells have different strategies towards the Ca2+-in-
duced mPTP and ROS generation, the observed differences in
the Ca2+-induced mPTP and ROS generation may be due to
the different organs and species used experimentally (Panov
et al. 2007). Therefore, the differences in mPTP properties in
diverse tissues might be caused by different proteins/isoforms
that participate in the function/regulation of pore opening.
mPTP as a target for neuroprotection
Once open, the mPTP collapses the mitochondrial membrane
potential, oxidative phosphorylation ceases and the ATPase
may even run in reverse accelerating ATP consumption and
driving necrotic cell death (Campanella et al. 2009). However,
mPTP opening also induces mitochondrial swelling and rup-
ture of the outer membrane leading to the release of pro-
apoptotic proteins, including cytochrome c and apoptosis-
inducing factor, from the mitochondrial intermembrane space
into the cytoplasm (Hengartner 2000; Hirsch et al. 1997;
Martinou and Green 2001). As a consequence, mPTP induc-
tion may progress to apoptotic cell death (Fiskum 2000;
Hirsch et al. 1997), although this will depend crucially on
the glycolytic capacity of the cell as apoptosis is ATP depen-
dent. Neuroprotection by CsA, the canonical inhibitor of the
mPTP, is most clearly established in the context of stroke—i.e.
ischemia-induced brain injury (Shiga et al. 1992). The mech-
anism of this protection is ambiguous as CsA also inhibits
calcineurin, which is also implicated in ischaemic neuronal
injury, but cerebral infarct size is reduced in CypD knockout
mice (Wang et al. 2009) lending support to a specific role of
the mPTP in stroke. In the heart, a role for the mPTP in injury
following ischaemia and reperfusion is sufficiently compel-
ling to support clinical trials (Piot et al. 2008). Sanglifehrin-A,
another, compound which inhibits mPTP opening, protected
myocytes from ischaemia-reperfusion injury (Hausenloy et al.
2003). We are not aware of studies using this compound in
stroke models.
The mPTP has also been implicated in AD pathophysiolo-
gy, as exposure of neurons to Aβ peptides lower the threshold
for mPTP induction (Moreira et al. 2001). The Aβ exposure
caused the progressive loss of mitochondrial membrane po-
tential in astrocytes, accompanied by transient mitochondrial
depolarisations caused by reversible openings of the mPTP
driven by sporadic calcium signals combined with oxidative
stress driven by activation of the NADPH oxidase. The tran-
sient mitochondrial depolarisatons were inhibited by CsA and
were absent in cultures from CypD knockout mice (Abeti
et al. 2011; Abramov et al. 2004a, 2004b, 2007). CypD
deficiency improved learning and memory and synaptic func-
tion in an AD mouse model and alleviated Aβ-mediated
reductions in long term potentiation (Du et al. 2008). Also,
disease onset and life expectancy of G93A-SOD1 mice (a
model of ALS) were significantly increased in animals in
which CypD was knocked out. The effect of CypD deletion
was much more prominent in females than in males (Martin
et al. 2009).
Recently, it was shown that the loss of DJ1 (a gene linked to
recessively inherited forms of PD), increased the rate of ROS
production, associated with a reduced mitochondrial trans-
membrane potential and increased probability of mPTP open-
ing (Giaime et al. 2012), all the changes were restored by
antioxidant treatment. Similarly, the loss of PINK1 increased
mitochondrial Ca2+ and increased the probability of mPTP
opening (Gautier et al. 2012). Our own work suggested that
PINK1 knockout caused impaired mitochondrial sodium cal-
cium exchange activity leading to mitochondrial calcium
overload and mPTP opening (Gandhi et al. 2009). It is not at
all clear how these roles for PINK1 match with its apparent
role in driving mitochondrial autophagy. Dopamine itself
seems to cause oxidative stress in dopaminergic neurons,
and exposure of PINK1 knockout cells to dopamine led to
mitochondrial depolarisation caused by mPTP opening. The
dopamine-induced mPTP opening, and dopamine-induced
cell death, were prevented by inhibition of ROS production,
by provision of respiratory chain substrates, and by reducing
Ca2+ signals (Gandhi et al. 2012).
A reduction of the oxidation of critical thiol groups of the
mPTP, which sensitize pore opening to Ca2+, represents a mech-
anism involved in preconditioning-mediated inhibition of mPTP
opening (Halestrap et al. 2007). In a recent study, it was demon-
strated that the treatment of mutant huntingtin-expressing cells
(STHdhQ111/Q111) and cortical neurons expressing mutant
huntingtin, with thapsigargin (a SERCA antagonist that releases
ER Ca2+, raising cytosolic [Ca2+] levels), decreased mitochon-
drial membrane potential and caused cell death. The data sug-
gested that thapsigargin induced opening ofmPTP in striatal cells
expressing mutant huntingtin, as the effects were prevented by
pre-treatment with CsA (Quintanilla et al. 2013). These findings
are consistent with the observations that CAG (polyglutamine
repeats) sensitise mitochondria to Ca2+ induced depolarisation
(Panov et al. 2002) and support a possible role for the pore in the
pathophysiology of HD. The factors related to mPTP implicated
in neuroprotection are summarised in (Fig. 1).
Conclusion
Accumulating evidence has pointed to a major role for mito-
chondrial dysfunction inmany of the major neurodegenerative
disorders. In some cases mitochondrial dysfunction seems a
primary mechanism driving the pathophysiology, whilst in
others the mitochondria lie on the pathways to cell death as
targets of other primary pathologies. In either case, under-
standing the mechanisms that converge on mitochondria
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may help define novel therapeutic strategies for these other-
wise largely intractable appalling diseases.
Given that mitochondrial dysfunction is an early patholog-
ical feature of several neurodegenerative diseases, targeting
impaired pathways of mitochondrial homeostasis may repre-
sent a powerful therapeutic strategy for treatment of the dis-
eases in their early stages. Mitochondrial dysfunction may
increase ROS generation, cause abnormal protein–protein
interactions, and of course may compromise cellular bioener-
getic integrity or lead to cell death. Therefore, therapeutic
approaches focussing primarily on mitochondrial homeostasis
may improve mitochondrial function and ameliorate the dam-
age in neurodegenerative diseases. Finally, understanding the
molecular mechanisms will bring new insights into the roles
of mitochondrial homeostasis in normal and pathological
conditions and could provide new therapeutic alternatives.
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